Last reviewed · How we verify
ICG R15
ICG R15 is an indocyanine green (ICG) derivative that fluoresces in the near-infrared spectrum for real-time visualization of liver function and blood flow during surgery.
ICG R15 is an indocyanine green (ICG) derivative that fluoresces in the near-infrared spectrum for real-time visualization of liver function and blood flow during surgery. Used for Intraoperative assessment of liver function and perfusion during hepatic surgery, Real-time visualization of hepatic blood flow and viability during liver resection.
At a glance
| Generic name | ICG R15 |
|---|---|
| Also known as | Indocyanine green retention test |
| Sponsor | Seoul National University Hospital |
| Drug class | Near-infrared fluorescent contrast agent |
| Modality | Small molecule |
| Therapeutic area | Surgery/Hepatology |
| Phase | FDA-approved |
Mechanism of action
ICG R15 is a modified indocyanine green contrast agent that binds to plasma proteins and is rapidly taken up and excreted by hepatocytes. The near-infrared fluorescence allows surgeons to visualize liver perfusion, assess hepatic function intraoperatively, and identify areas of compromised blood supply in real time, enabling safer hepatic resection.
Approved indications
- Intraoperative assessment of liver function and perfusion during hepatic surgery
- Real-time visualization of hepatic blood flow and viability during liver resection
Common side effects
- Allergic reactions (rare)
- Transient hypotension
- Flushing
Key clinical trials
- Multi-center Clinical Study on the Decision Tree of Precision Hepatectomy in China Precision Hepatectomy Decision Tree
- Prognostic Role of HVPG and ICG-R15 in the Short- and Medium-term Results of the Surgery of HCC on Cirrhosis
- On the Cyberknife Dose Fraction of Liver Cancer Treatment
- Indocyanine Green and Portal Pressure in Viral and Alcoholic Cirrhotic Patients With Hepatocarcinoma
- Evaluation of Hepatic Function Using Gadoxetic Acid Enhanced MRI (PHASE4)
- Evaluation of Remnant Liver Function Using Primovist-enhanced MRI Before Resection/Ablation of Hepatocellular Carcinoma
- Cardiox Liver Function Test Pivotal Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ICG R15 CI brief — competitive landscape report
- ICG R15 updates RSS · CI watch RSS
- Seoul National University Hospital portfolio CI